High HOXB13 expression was associated with better overall survival in only RCC patients (compared with low HOXB13 expression; median survival times were 183 and 132 months, respectively, P = 0.032) (Fig. 1c–e). This evidence concerns the gene HOXB13 and renal cell carcinoma.